EcoDrugPlus

Solute Carrier Family 5 Member 1

Ensembl ID : ENSLCRG00005013663
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSLCRG00005009308
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSLCRG00005007120
Gene Symbol: SLC6A1A
3 Cross references
205 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSLCRG00005005535
Gene Symbol: SLC6A1B
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSLCRG00005023232
Gene Symbol: SLC6A2
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSLCRG00005017387
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4a

Ensembl ID : ENSLCRG00005012865
Gene Symbol: SLC6A4A
3 Cross references
201 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSLCRG00005012839
Gene Symbol: SLC6A9
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSLCRG00005018001
Gene Symbol: SLC9A3
3 Cross references
234 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSLCRG00005008759
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSLCRG00005022485
Gene Symbol: SSTR2
3 Cross references
192 Possible Orthologues:

Somatostatin Receptor Type 5

Ensembl ID : ENSLCRG00005008577
Gene Symbol: LOC104925456
2 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).